{"id":"W4366083620","doi":"10.1182/bloodadvances.2022009260","title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; MorphoSys; Juno Therapeutics; Adaptive Biotechnologies; Celltrion; Celgene; Alimera Sciences; BeiGene; MEI Pharma; Sunesis; TG Therapeutics; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Yuhan; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Gastroenterology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001092143,0.000204454,0.000343438,0.0002263533,0.00008296247,0.00002423632,0.0000998563,0.00008557074,0.0002963129],"category_scores_gemma":[0.00002086082,0.0001609794,0.0000426192,0.0005354319,0.00007880504,0.0002763665,0.00004690667,0.0001829703,0.00003753438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007931291,"about_ca_system_score_gemma":0.000087758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005162571,"about_ca_topic_score_gemma":0.00005639603,"domain_scores_codex":[0.998395,0.00004863529,0.0001963099,0.0004290475,0.0004467792,0.0004842558],"domain_scores_gemma":[0.9992574,0.0001232448,0.00007204143,0.000327931,0.00007813681,0.0001412674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009323292,0.01430889,0.7826823,0.000302545,0.0002868083,0.0002369594,0.005222433,0.00001059842,0.01130689,0.00003132693,0.0006563194,0.1756316],"study_design_scores_gemma":[0.1598703,0.004207862,0.6314558,0.0002947755,0.00008677239,0.000009985585,0.001259423,0.000225797,0.04815463,0.0002315225,0.1536018,0.0006012435],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945325,0.001502383,0.000003161806,0.0001495879,0.00005734706,0.0006238326,0.00003918458,0.00008824743,0.003003738],"genre_scores_gemma":[0.9858951,0.003284601,0.0001652964,0.0003722461,0.00006186047,0.00007601341,0.00004431565,0.00006287171,0.01003771],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1750304,"threshold_uncertainty_score":0.6564549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008757305009623545,"score_gpt":0.261308908155294,"score_spread":0.2525516031456705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}